Saniona AB (CHIX:SANIOS) Other Current Payables: kr0.0 Mil (As of Mar. 2026)


CHIX:SANIOS Saniona AB CHIX:SANIOS
66 GF Score
Price kr12.75
GF Value kr26.73
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Saniona AB Other Current Payables?

Saniona AB CHIX:SANIOS 66 Other Current Payables is kr0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:SANIOS with a GF Score™ of 66/100 and a GF Value™ of kr26.73 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Saniona AB's Other Current Payables for the quarter that ended in Mar. 2026 was kr0.0 Mil.

Saniona AB's annual Other Current Payables declined from Dec. 2023 (kr0.0 Mil) to Dec. 2024 (kr-0.0 Mil) but then increased from Dec. 2024 (kr-0.0 Mil) to Dec. 2025 (kr0.0 Mil).

Saniona AB Other Current Payables Related Terms

Saniona AB Other Current Payables Historical Data

* Premium members only.

The historical data trend for Saniona AB's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Saniona AB Other Current Payables Chart

Saniona AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

Saniona AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:SANIOS
66GF Score
Saniona AB CHIX:SANIOS
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Saniona AB Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of kr0.0 Mil mean?
Saniona AB (CHIX:SANIOS) has a Other Current Payables of kr0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Saniona AB and its competitors.
Is Saniona AB's Other Current Payables too high?
Saniona AB's current Other Current Payables is kr0.0 Mil. Overall, Saniona AB has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's Other Current Payables compare to VRTX and REGN?
Saniona AB's Other Current Payables of kr0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Saniona AB and its competitors. Saniona AB's current Other Current Payables is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr26.73, compared to a current price of kr12.75 — trading 52.3% below its estimated fair value. The current Other Current Payables is kr0.0 Mil. Saniona AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current Other Current Payables is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?

Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued. The current stock price of kr12.75 is trading 52.3% below its estimated GF Value™ of kr26.73. GuruFocus considers Saniona AB to be Significantly Undervalued.

Key valuation signals for CHIX:SANIOS:

  • Other Current Payables: kr0.0 Mil
  • GF Value™: kr26.73 vs. price of kr12.75 (52.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Saniona AB Business Description

Address Murervangen 42, Glostrup, DNK, DK-2600
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
66GF Score

Get the complete analysis for CHIX:SANIOS

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.75
Price
kr26.73
GF Value